Sayumi Yamazoe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sayumi Yamazoe has a total of 142 co-authors. Here are the top co-authors by number of shared publications:
Arvind Rajpal
Research and Development Bristol Myers Squibb Redwood City CA 94063 USA
6 shared publicationsChetana Rao
Research and Development Bristol Myers Squibb Redwood City CA 94063 USA
4 shared publicationsGavin Dollinger
Bristol Myers Squibb Research and Development Redwood City California 94063 United States
4 shared publicationsMadhura Deshpande
Bristol Myers Squibb Research and Development Redwood City California 94063 United States
4 shared publicationsMiranda Broz
Bristol-Myers Squibb Research & Development, 700 Bay Road, Redwood City, California 94063, USA
4 shared publicationsPavel Strop
Research and Development Bristol Myers Squibb Redwood City CA 94063 USA
4 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Development of oligo-thioester precursors for native chemical ligation of oligo-protein conjugates.
Protein-oligo conjugates have emerged as a promising therapeutic modality that unites the target-specificity and favorable pharmacokinetics of a protein carrier with the potency of an oligonucleotide payload. One challenge in the development of these biologics is that conjugation strategies often yield heterogeneous, high drug-to-antibody ratio (DAR) products or require non-canonical amino acids and multi-step handling. Native chemical ligation (NCL) is a promising tool for protein-oligo conjugation, as the reaction is single-step and regiospecific to N-terminal cysteines, which can be genetically installed into proteins in a facile manner. However, methods for generating the required oligo-thioesters remain a technical challenge, especially when complex linker groups are desired. Here, we report an efficient protocol to generate four oligo linker-payloads (LPs) incorporating an anti-sense oligonucleotide targeting the MALAT1 gene, bis(2-sulfanylethyl)amine (NSS)- or thioacid-based thioester precursors, and diverse intervening linkers. The LPs were successfully ligated to an affibody and the crystallizable fragment (Fc) of an antibody, key protein carriers for protein-oligo therapeutics. The operationally simple, bespoke nature of this workflow enables the diversification of oligo payloads and linkers required for broad applications.
- 23 October 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessDevelopment of oligo-thioester precursors for native chemical ligation of oligo-protein conjugates.
Protein-oligo conjugates have emerged as a promising therapeutic modality that unites the target-specificity and favorable pharmacokinetics of a protein carrier with the potency of an oligonucleotide payload. One challenge in the development of these biologics is that conjugation strategies often yield heterogeneous, high drug-to-antibody ratio (DAR) products or require non-canonical amino acids and multi-step handling. Native chemical ligation (NCL) is a promising tool for protein-oligo conjugation, as the reaction is single-step and regiospecific to N-terminal cysteines, which can be genetically installed into proteins in a facile manner. However, methods for generating the required oligo-thioesters remain a technical challenge, especially when complex linker groups are desired. Here, we report an efficient protocol to generate four oligo linker-payloads (LPs) incorporating an anti-sense oligonucleotide targeting the MALAT1 gene, bis(2-sulfanylethyl)amine (NSS)- or thioacid-based thioester precursors, and diverse intervening linkers. The LPs were successfully ligated to an affibody and the crystallizable fragment (Fc) of an antibody, key protein carriers for protein-oligo therapeutics. The operationally simple, bespoke nature of this workflow enables the diversification of oligo payloads and linkers required for broad applications.
- Open Access
- 28 October 2025
- Published by Wiley in ChemBioChem
- Vol. 26 (22) , e202500304
Design and Characterization of Prodrugged Anti‐CTLA‐4 Antibodies
Therapeutic antibodies are widely used to treat diseases like cancer and inflammatory conditions by binding with high specificity to their molecular targets. Masking is a strategy to mitigate undesirable activity in nontarget tissues, improving safety and pharmacokinetic (PK) profiles by reducing target‐mediated drug disposition. In this article, masking of an anti‐CTLA‐4 antibody by conjugating a large PEG molecule to specific sites on the antibody is explored. While anti‐CTLA‐4 immunotherapy benefits solid tumor treatment, its adverse events limit its utility. Multiple conjugation sites within the complementarity‐determining regions and adjacent framework regions are evaluated to attenuate CTLA‐4 binding. The optimal site for maximizing masking efficiency is identified, allowing for efficient bioconjugation and functional restoration upon exposure to a cleaving enzyme in the tumor microenvironment. The prodrugged antibody exhibits reduced binding to CTLA‐4 and Fc gamma receptors, high stability, and an extended half‐life in a mouse model. This technology has the potential to improve the PK profile and safety attributes of therapeutic antibodies.
- 28 October 2025
- Published by Wiley in ChemBioChem
- Vol. 26 (22) , e202500304
Open AccessDesign and Characterization of Prodrugged Anti‐CTLA‐4 Antibodies
Therapeutic antibodies are widely used to treat diseases like cancer and inflammatory conditions by binding with high specificity to their molecular targets. Masking is a strategy to mitigate undesirable activity in nontarget tissues, improving safety and pharmacokinetic (PK) profiles by reducing target‐mediated drug disposition. In this article, masking of an anti‐CTLA‐4 antibody by conjugating a large PEG molecule to specific sites on the antibody is explored. While anti‐CTLA‐4 immunotherapy benefits solid tumor treatment, its adverse events limit its utility. Multiple conjugation sites within the complementarity‐determining regions and adjacent framework regions are evaluated to attenuate CTLA‐4 binding. The optimal site for maximizing masking efficiency is identified, allowing for efficient bioconjugation and functional restoration upon exposure to a cleaving enzyme in the tumor microenvironment. The prodrugged antibody exhibits reduced binding to CTLA‐4 and Fc gamma receptors, high stability, and an extended half‐life in a mouse model. This technology has the potential to improve the PK profile and safety attributes of therapeutic antibodies.
- 12 August 2025
- Published by American Chemical Society (ACS) in ACS Chemical Biology
Design and Characterization of an Anti-Clec9a Antibody Armed with CpG Oligonucleotides To Enable Targeted Delivery of Adjuvant to Cross-Presenting Dendritic Cells
C-type lectin receptor, Clec9a, is a highly specific receptor expressed on cross-presenting conventional dendritic cells (cDC1). This receptor specificity for this rare population of dendritic cells (DCs), combined with their inherent ability to internalize and localize to the endocytic compartment, presents a unique opportunity for targeted delivery of innate immune agonists. By leveraging an anti-Clec9a antibody, we can specifically deliver these agonists to cross-presenting cDCs, thereby enhancing the cross-priming and expansion of tumor-specific cytotoxic T lymphocytes (CTLs). In this study, we detail the design and characterization of innovative bioconjugates composed of a Clec9a-targeting antibody and CpG oligodeoxynucleotides (ODNs), which activate Toll-like receptor 9 (TLR9) expressed by cDC1. These immunomodulatory bioconjugates exhibited significant cellular activity in cross-presentation assays within a coculture system of in vitro generated CD103+ DCs (iCD103 DCs), tumor cells, and antigen specific CTLs, driving robust cross priming. Furthermore, the targeted delivery of ODNs to cDC1 in vivo demonstrated target-dependent activity in a murine vaccination assay. Our findings underscore the potential of Clec9a-targeted bioconjugates as a powerful strategy to enhance antitumor immunity by precisely delivering adjuvants to cross-presenting dendritic cells.
- 12 August 2025
- Published by American Chemical Society (ACS) in ACS Chemical Biology
Design and Characterization of an Anti-Clec9a Antibody Armed with CpG Oligonucleotides To Enable Targeted Delivery of Adjuvant to Cross-Presenting Dendritic Cells
C-type lectin receptor, Clec9a, is a highly specific receptor expressed on cross-presenting conventional dendritic cells (cDC1). This receptor specificity for this rare population of dendritic cells (DCs), combined with their inherent ability to internalize and localize to the endocytic compartment, presents a unique opportunity for targeted delivery of innate immune agonists. By leveraging an anti-Clec9a antibody, we can specifically deliver these agonists to cross-presenting cDCs, thereby enhancing the cross-priming and expansion of tumor-specific cytotoxic T lymphocytes (CTLs). In this study, we detail the design and characterization of innovative bioconjugates composed of a Clec9a-targeting antibody and CpG oligodeoxynucleotides (ODNs), which activate Toll-like receptor 9 (TLR9) expressed by cDC1. These immunomodulatory bioconjugates exhibited significant cellular activity in cross-presentation assays within a coculture system of in vitro generated CD103+ DCs (iCD103 DCs), tumor cells, and antigen specific CTLs, driving robust cross priming. Furthermore, the targeted delivery of ODNs to cDC1 in vivo demonstrated target-dependent activity in a murine vaccination assay. Our findings underscore the potential of Clec9a-targeted bioconjugates as a powerful strategy to enhance antitumor immunity by precisely delivering adjuvants to cross-presenting dendritic cells.
- Open Access
- 28 May 2025
- Published by Wiley in ChemistryOpen
- Vol. 14 (8) , e2400522
The Impact of Conjugation Mode and Site on Tubulysin Antibody‐Drug‐Conjugate Efficacy and Stability
Antibody‐drug conjugates (ADCs) represent a prominent class of biotherapeutics engineered to selectively deliver cytotoxic payloads to tumors, thereby facilitating targeted cell killing. While first‐generation ADCs, created by conjugating payloads to surface‐accessible lysine or hinge‐cysteine residues, have achieved clinical success, several site‐specific ADCs with defined drug‐to‐antibody ratios are currently under clinical investigation. Herein, the efficacy, stability, and pharmacokinetics of ADCs generated by attaching the drug linker to surface‐exposed lysine residues, hinge‐cysteine residues, and the C’E loop in the CH2 domain (mediated by bacterial transglutaminase) using a tubulysin payload are compared. In N87 xenograft mice, the order of efficacy is C’E loop > hinge‐cysteine > lysine‐conjugated ADCs. Among the three ADCs evaluated, the site‐specific ADC demonstrates superior in vivo stability (minimal payload‐linker deconjugation and limited payload metabolism/deacetylation) and favorable pharmacokinetics (longer half‐life, low clearance, high exposure). In contrast, the lysine‐conjugated ADC exhibits the least stability and poorest pharmacokinetics, which directly correlate with its efficacy. Further investigation into cysteine‐engineered site‐specific ADCs with payloads conjugated at various sites confirms that both the conjugation chemistry and the site of conjugation significantly influence the in vivo stability and pharmacokinetics of site‐specific ADCs.
- 28 May 2025
- Published by Wiley in ChemistryOpen
- Vol. 14 (8) , e2400522
Open AccessThe Impact of Conjugation Mode and Site on Tubulysin Antibody‐Drug‐Conjugate Efficacy and Stability
Antibody‐drug conjugates (ADCs) represent a prominent class of biotherapeutics engineered to selectively deliver cytotoxic payloads to tumors, thereby facilitating targeted cell killing. While first‐generation ADCs, created by conjugating payloads to surface‐accessible lysine or hinge‐cysteine residues, have achieved clinical success, several site‐specific ADCs with defined drug‐to‐antibody ratios are currently under clinical investigation. Herein, the efficacy, stability, and pharmacokinetics of ADCs generated by attaching the drug linker to surface‐exposed lysine residues, hinge‐cysteine residues, and the C’E loop in the CH2 domain (mediated by bacterial transglutaminase) using a tubulysin payload are compared. In N87 xenograft mice, the order of efficacy is C’E loop > hinge‐cysteine > lysine‐conjugated ADCs. Among the three ADCs evaluated, the site‐specific ADC demonstrates superior in vivo stability (minimal payload‐linker deconjugation and limited payload metabolism/deacetylation) and favorable pharmacokinetics (longer half‐life, low clearance, high exposure). In contrast, the lysine‐conjugated ADC exhibits the least stability and poorest pharmacokinetics, which directly correlate with its efficacy. Further investigation into cysteine‐engineered site‐specific ADCs with payloads conjugated at various sites confirms that both the conjugation chemistry and the site of conjugation significantly influence the in vivo stability and pharmacokinetics of site‐specific ADCs.
- Open Access
- 24 May 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (11) , 11322-11339
Discovery and Characterization of a First-in-Class LIV1-TLR7/8 Immunomodulatory Conjugate with Robust Myeloid Activation and Antitumor Activity
Herein, we describe the discovery of a novel immunostimulatory drug conjugate (IMC) that employs TLR7/8 agonists conjugated to a tumor-targeting LIV1 antibody. Targeting TLR7/8 agonists to LIV1-expressing tumors enables localized delivery, thereby minimizing systemic toxicity while promoting inflammation and T cell recruitment within the tumor microenvironment (TME) for enhanced antitumor efficacy. Dual activation of TLR7 and TLR8 within the TME facilitates the recruitment of diverse immune cells and induces a broad spectrum of pro-inflammatory cytokines, effectively reshaping the immunosuppressive TME by upregulating costimulatory molecules. The mechanism of action of the IMC involves tumor recognition via surface antigens and Fcγ-mediated phagocytosis, followed by activation of myeloid cells to efficiently present tumor antigens to T-cells, thereby eliciting antitumor immunity. The designed IMCs demonstrate the ability to activate myeloid cells in the presence of tumor cells, display robust antitumor activity, and are well tolerated in toxicology studies.
- 24 May 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (11) , 11322-11339
Open AccessDiscovery and Characterization of a First-in-Class LIV1-TLR7/8 Immunomodulatory Conjugate with Robust Myeloid Activation and Antitumor Activity
Herein, we describe the discovery of a novel immunostimulatory drug conjugate (IMC) that employs TLR7/8 agonists conjugated to a tumor-targeting LIV1 antibody. Targeting TLR7/8 agonists to LIV1-expressing tumors enables localized delivery, thereby minimizing systemic toxicity while promoting inflammation and T cell recruitment within the tumor microenvironment (TME) for enhanced antitumor efficacy. Dual activation of TLR7 and TLR8 within the TME facilitates the recruitment of diverse immune cells and induces a broad spectrum of pro-inflammatory cytokines, effectively reshaping the immunosuppressive TME by upregulating costimulatory molecules. The mechanism of action of the IMC involves tumor recognition via surface antigens and Fcγ-mediated phagocytosis, followed by activation of myeloid cells to efficiently present tumor antigens to T-cells, thereby eliciting antitumor immunity. The designed IMCs demonstrate the ability to activate myeloid cells in the presence of tumor cells, display robust antitumor activity, and are well tolerated in toxicology studies.
- 29 April 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (9) , 9799-9810
Antibody-Drug Conjugates of NLRP3 Agonists: How Overcoming Lysosomal Accumulation Necessitated Noncanonical Linker Attachments
An initial series of NLRP3 agonist antibody-drug conjugates (ADCs) failed to induce IL-1β in vitro due to lysosomal trapping of the payload. To address this, we developed assays and computational tools to identify a new payload that could diffuse out of the lysosomes. ADCs derived from this payload were active, emphasizing the need to avoid payload lysosomal accumulation for nonlysosomal targets. Two active ADCs necessitated attaching a cleavable valine-citrulline recognition element to the payload via a noncanonical ester linkage, rather than a canonical carbamate one, since the payload did not contain a basic amine. The citrulline stereocenter configuration was found to affect the payload release and in vitro activity. The ADC with the (L)-Val-(L)-Cit ester configuration showed superior in vitro activity, high stability in mouse serum, and rapid cleavage in human liver lysosomes. These properties suggest that this noncanonical (L)-Val-(L)-Cit ester attachment may be valuable to the ADC community moving forward.
- 29 April 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (9) , 9799-9810
Antibody-Drug Conjugates of NLRP3 Agonists: How Overcoming Lysosomal Accumulation Necessitated Noncanonical Linker Attachments
An initial series of NLRP3 agonist antibody-drug conjugates (ADCs) failed to induce IL-1β in vitro due to lysosomal trapping of the payload. To address this, we developed assays and computational tools to identify a new payload that could diffuse out of the lysosomes. ADCs derived from this payload were active, emphasizing the need to avoid payload lysosomal accumulation for nonlysosomal targets. Two active ADCs necessitated attaching a cleavable valine-citrulline recognition element to the payload via a noncanonical ester linkage, rather than a canonical carbamate one, since the payload did not contain a basic amine. The citrulline stereocenter configuration was found to affect the payload release and in vitro activity. The ADC with the (L)-Val-(L)-Cit ester configuration showed superior in vitro activity, high stability in mouse serum, and rapid cleavage in human liver lysosomes. These properties suggest that this noncanonical (L)-Val-(L)-Cit ester attachment may be valuable to the ADC community moving forward.
- Open Access
- 13 February 2025
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 36 (3) , 437-448
Targeted Delivery of TLR7 Agonists to the Tumor Microenvironment Enhances Tumor Immunity via Activation of Tumor-Resident Myeloid Cells
Toll-like receptors (TLR) are phylogenetically conserved mediators of innate immunity that are essential for establishing adaptive immune responses against invading pathogens. TLR7 is an endosomal receptor expressed predominantly in myeloid and B cells. Activation of TLR7 induces Type I interferon and proinflammatory responses; therefore, targeting TLR7 is a promising strategy for antitumor therapy. Although the use of bacterial components to trigger innate immune responses in cancer patients started a century ago, the effectiveness of systemic TLR agonists has been rather underwhelming in clinical trials, partly due to nonspecific immune activation leading to safety and tolerability issues. Antibody-drug conjugates (ADCs) constitute a proven therapeutic modality amenable to systemic administration with limited toxicity concerns via a targeted delivery platform. We generated TLR7 agonist-antibody conjugates that recognize tumor antigens expressed on the surface of tumor cells. Generated ADCs demonstrated robust activity in in vitro tumor antigen-presenting cell (APC) coculture systems as indicated by dose-dependent upregulation of PD-L1 and CD86 on macrophages. TLR7 agonist-ADC provided superior tumor growth control compared to intravenously (IV) administrated free TLR7 agonist. Treatment with TLR7 agonist-ADC led to prolonged activation of myeloid cells in the tumor microenvironment (TME) with minimum immune activation in the periphery. Systemic and tissue exposure studies demonstrated tumor-specific free drug release by targeted ADC treatment. In summary, the TLR7 agonist-ADC can potentially activate immune cells in the TME to generate tumor antigen-specific T-cell responses, making it an attractive approach for precision cancer therapy.
- 13 February 2025
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 36 (3) , 437-448
Open AccessTargeted Delivery of TLR7 Agonists to the Tumor Microenvironment Enhances Tumor Immunity via Activation of Tumor-Resident Myeloid Cells
Toll-like receptors (TLR) are phylogenetically conserved mediators of innate immunity that are essential for establishing adaptive immune responses against invading pathogens. TLR7 is an endosomal receptor expressed predominantly in myeloid and B cells. Activation of TLR7 induces Type I interferon and proinflammatory responses; therefore, targeting TLR7 is a promising strategy for antitumor therapy. Although the use of bacterial components to trigger innate immune responses in cancer patients started a century ago, the effectiveness of systemic TLR agonists has been rather underwhelming in clinical trials, partly due to nonspecific immune activation leading to safety and tolerability issues. Antibody-drug conjugates (ADCs) constitute a proven therapeutic modality amenable to systemic administration with limited toxicity concerns via a targeted delivery platform. We generated TLR7 agonist-antibody conjugates that recognize tumor antigens expressed on the surface of tumor cells. Generated ADCs demonstrated robust activity in in vitro tumor antigen-presenting cell (APC) coculture systems as indicated by dose-dependent upregulation of PD-L1 and CD86 on macrophages. TLR7 agonist-ADC provided superior tumor growth control compared to intravenously (IV) administrated free TLR7 agonist. Treatment with TLR7 agonist-ADC led to prolonged activation of myeloid cells in the tumor microenvironment (TME) with minimum immune activation in the periphery. Systemic and tissue exposure studies demonstrated tumor-specific free drug release by targeted ADC treatment. In summary, the TLR7 agonist-ADC can potentially activate immune cells in the TME to generate tumor antigen-specific T-cell responses, making it an attractive approach for precision cancer therapy.
- 19 December 2024
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16 (1) , 80-88
Structure-Based Design of Novel TLR7/8 Agonist Payloads Enabling an Immunomodulatory Conjugate Approach
Dual activation of the TLR7 and TLR8 pathways leads to the production of type I interferon and proinflammatory cytokines, resulting in efficient antigen presentation by dendritic cells to promote T-cell priming and antitumor immunity. We developed a novel series of TLR7/8 dual agonists with varying ratios of TLR7 and TLR8 activity for use as payloads for an antibody-drug conjugate approach. The agonist-induced production of several cytokines in human whole blood confirmed their functional activity. Structure-activity relationship studies guided by structure-based drug design are described.
- 19 December 2024
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16 (1) , 80-88
Structure-Based Design of Novel TLR7/8 Agonist Payloads Enabling an Immunomodulatory Conjugate Approach
Dual activation of the TLR7 and TLR8 pathways leads to the production of type I interferon and proinflammatory cytokines, resulting in efficient antigen presentation by dendritic cells to promote T-cell priming and antitumor immunity. We developed a novel series of TLR7/8 dual agonists with varying ratios of TLR7 and TLR8 activity for use as payloads for an antibody-drug conjugate approach. The agonist-induced production of several cytokines in human whole blood confirmed their functional activity. Structure-activity relationship studies guided by structure-based drug design are described.
- Open Access
- 28 March 2022
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 33 (4) , 576-585
Impact of Drug Conjugation on Thermal and Metabolic Stabilities of Aglycosylated and N-Glycosylated Antibodies
N-linked glycosylation is one of the most common and complex posttranslational modifications that govern the biological functions and physicochemical properties of therapeutic antibodies. We evaluated thermal and metabolic stabilities of antibody–drug conjugates (ADCs) with payloads attached to the C’E loop in the immunoglobulin G (IgG) Fc CH2 domain, comparing the glycosylated and aglycosylated Fc ADC variants. Our study revealed that introduction of small-molecule drugs into an aglycosylated antibody can compensate for thermal destabilization originating from structural distortions caused by elimination of N-linked glycans. Depending on the conjugation site, glycans had both positive and negative effects on plasma stability of ADCs. The findings highlight the importance of consideration for selection of conjugation site to achieve desirable physicochemical properties and plasma stability.
- 28 March 2022
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 33 (4) , 576-585
Open AccessImpact of Drug Conjugation on Thermal and Metabolic Stabilities of Aglycosylated and N-Glycosylated Antibodies
N-linked glycosylation is one of the most common and complex posttranslational modifications that govern the biological functions and physicochemical properties of therapeutic antibodies. We evaluated thermal and metabolic stabilities of antibody–drug conjugates (ADCs) with payloads attached to the C’E loop in the immunoglobulin G (IgG) Fc CH2 domain, comparing the glycosylated and aglycosylated Fc ADC variants. Our study revealed that introduction of small-molecule drugs into an aglycosylated antibody can compensate for thermal destabilization originating from structural distortions caused by elimination of N-linked glycans. Depending on the conjugation site, glycans had both positive and negative effects on plasma stability of ADCs. The findings highlight the importance of consideration for selection of conjugation site to achieve desirable physicochemical properties and plasma stability.
- 22 March 2021
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 93 (13) , 5371-5376
Automated and Faster Affinity Capture Method for Biotransformation Assessment of Site-Specific Antibody Drug Conjugates
Traditionally the biotransformation of antibody drug conjugates (ADCs) has been evaluated by affinity capture on streptavidin magnetic beads coated with a biotinylated capture reagent. To reduce the complexity of the analyte, the affinity captured ADCs are digested with enzymes (“on-bead” or after elution), and/or interchain disulfides are reduced to generate LC and HC fragments prior to mass spectrometry analysis. The “on-bead” enzymatic digestion with IdeS and PNGase F is not efficient and requires longer incubation times to achieve complete Fc and N-glycan removal. This results in a prolonged sample preparation time (7–18 h) and is not suitable for labile ADCs due to the possibility of assay-induced artifacts. To address these challenges, we developed an affinity capture method, where the ADCs are first captured onto streptavidin cartridges coated with a biotinylated generic capture reagent, followed by a 15 min “on-cartridge” digestion with IdeS or PNGase F. The ADCs are then eluted and directly analyzed by LC-HRMS. This method was successfully applied for the biotransformation assessment of site-specific ADCs with payload conjugated on the Fab or Fc. The reduced complexity of the analyte (Fc and N-glycan removal) combined with HRMS enabled sensitive and accurate identification of minor mass change catabolites and changes in the DAR distribution. This automated cartridge-based affinity capture method is fast with a total sample preparation time of less than 4 h (hands-on time of less than 1 h) and can be utilized for any human mAb/ADC independent of isotype (IgG1, IgG2, and IgG4).
- 22 March 2021
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 93 (13) , 5371-5376
Automated and Faster Affinity Capture Method for Biotransformation Assessment of Site-Specific Antibody Drug Conjugates
Traditionally the biotransformation of antibody drug conjugates (ADCs) has been evaluated by affinity capture on streptavidin magnetic beads coated with a biotinylated capture reagent. To reduce the complexity of the analyte, the affinity captured ADCs are digested with enzymes (“on-bead” or after elution), and/or interchain disulfides are reduced to generate LC and HC fragments prior to mass spectrometry analysis. The “on-bead” enzymatic digestion with IdeS and PNGase F is not efficient and requires longer incubation times to achieve complete Fc and N-glycan removal. This results in a prolonged sample preparation time (7–18 h) and is not suitable for labile ADCs due to the possibility of assay-induced artifacts. To address these challenges, we developed an affinity capture method, where the ADCs are first captured onto streptavidin cartridges coated with a biotinylated generic capture reagent, followed by a 15 min “on-cartridge” digestion with IdeS or PNGase F. The ADCs are then eluted and directly analyzed by LC-HRMS. This method was successfully applied for the biotransformation assessment of site-specific ADCs with payload conjugated on the Fab or Fc. The reduced complexity of the analyte (Fc and N-glycan removal) combined with HRMS enabled sensitive and accurate identification of minor mass change catabolites and changes in the DAR distribution. This automated cartridge-based affinity capture method is fast with a total sample preparation time of less than 4 h (hands-on time of less than 1 h) and can be utilized for any human mAb/ADC independent of isotype (IgG1, IgG2, and IgG4).